Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
OncoHost General Information
OncoHost has developed and commercialized the PROphet® precision oncology diagnostic platform. This blood-based test uses high-throughput proteomics (~7,000 proteins analyzed per sample) and machine learning to predict which patients with advanced cancers—starting with non-small cell lung cancer—are likely to benefit from PD‑1/PD‑L1 inhibitor therapies. The technology provides actionable insights before treatment initiation, aiming to overcome resistance mechanisms and improve patient outcomes. Clinical validation includes a large global trial network.
Contact Information
Website
Primary Industry
Protein Biomarker Diagnostics
Corporate Office
,
Israel
Israel
Drug Pipeline
No pipeline data available
Key Partnerships
None publicly disclosed beyond clinical trial network
OncoHost Funding
No funding data available
To view OncoHost's complete valuation and funding history, request access »